Key clinical point: Secukinumab demonstrated rapid improvements in clinical outcomes and showed a consistent safety profile in challenging-to-treat patients with psoriatic arthritis (PsA) who had high BMI and showed higher tender and swollen joints despite previous treatment.
Major finding: At week 16, patients receiving secukinumab 300 mg and 150 mg with loading dose vs placebo had a higher rate of achieving the American College of Rheumatology 20 response (59.7% and 43.4%, respectively, vs 15.6%; both P < .0001) and the Psoriasis Area and Severity Index 90 response (47.1% and 22.2%, respectively, vs 5.3%; both P < .05).
Study details: This subgroup analysis of four phase 3 FUTURE studies included 279 patients with challenging-to-treat PsA from the United States who received secukinumab or placebo and had undergone prior treatment with nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, or corticosteroids.
Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, United States. Luminita Pricop declared being an employee and stockholder of Novartis. The other authors declared receiving research grants from or having other ties with Novartis or others.
Source: Kivitz AJ, Kremer JM, Legerton CW 3rd, Pricop L, Singhal A. Efficacy and safety of secukinumab in US patients with psoriatic arthritis: A subgroup analysis of the phase 3 FUTURE studies. Rheumatol Ther. Published online April 16, 2024. Source